INVA
Innoviva, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
21.07
▲ 0.07 (0.33%)
MARKET · —
Price
Open
20.73
Prev close
21.00
Day high
21.23
Day low
20.90
Volume
476.08K
Market cap
$1.52B
P/E (TTM)
4.89
52W range
16.52 – 25.15
Trailing performance
Returnvs SPY
1W
-0.57%
+0.8%
1M
-0.61%
-4.3%
3M
-5.09%
-8.2%
6M
-9.92%
-21.0%
YTD
+5.40%
-6.9%
1Y
+5.61%
-14.4%
3Y
+55.27%
-18.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.52B
Enterprise value$1.27B
Revenue (TTM)$440.00M
Gross profit$319.75M
EBITDA$195.39M
Net income$357.24M
EPS (TTM)$4.31
Free cash flow$110.33M
Total cash$579.06M
Total debt$331.24M
Book value / share$16.98
Shares outstanding72.25M
Float67.65M
Short % of float12.95%
Dividend yield—
Beta (5Y)0.34
Valuation & profitability ratios
Trailing P/E4.89
Forward P/E9.53
PEG ratio0.31
Price / sales—
Price / book1.24
EV / revenue2.90
EV / EBITDA6.52
Gross margin72.67%
Operating margin43.28%
Profit margin81.19%
Return on equity36.68%
Return on assets6.95%
Debt / equity26.86
Current ratio16.01
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $411.33M | $358.71M | $310.46M | $331.34M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $271.17M | $0 | $0 | $0 |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $271.17M | $0 | $0 | $0 |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.50 | 0.56 | +11.5% |
| Mar 2026 | 0.43 | 0.47 | +8.8% |
| Dec 2025 | 0.43 | 0.47 | +11.1% |
| Sep 2025 | 0.39 | 0.38 | -0.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.46 | 1 | $114.13M | +5.9% |
| Next quarter | 0.52 | 1 | $118.05M | +3.0% |
| Current year | 1.91 | 1 | $446.53M | +8.6% |
| Next year | 2.21 | 1 | $488.66M | +9.4% |
Analyst targets & ownership
Mean target$35.00
High target$46.00
Low target$18.00
Implied upside66.11%
Analyst count4
ConsensusBUY
Strong buy / Buy0 / 3
Hold0
Sell / Strong sell1 / 0
Held by insiders1.01%
Held by institutions109.51%
Institutions holding425
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
730.40K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 18, 26 | LINDEN JOSEPHINE Director |
STOCK | 15.19K | $0 | Direct |
| May 15, 26 | RAIFELD PAVEL Chief Executive Officer |
STOCK | 1.12K | $0 | Direct |
| May 15, 26 | BASSO STEPHEN Chief Financial Officer |
STOCK | 1.12K | $0 | Direct |
| May 4, 26 | HAIMOVITZ JULES Director |
STOCK | 9.79K | $0 | Direct |
| May 4, 26 | SCHLESINGER SARAH J Director |
STOCK | 9.79K | $0 | Direct |
| May 4, 26 | SMALL DEREK A Director |
STOCK | 9.79K | $0 | Direct |
| May 4, 26 | DIPAOLO MARK A Director |
STOCK | 9.79K | $0 | Direct |
| May 4, 26 | ZHEN MARIANNE Y Officer |
STOCK | 12.77K | $0 | Direct |
| May 4, 26 | RAIFELD PAVEL Chief Executive Officer |
STOCK | 126.65K | $0 | Direct |
| May 4, 26 | BASSO STEPHEN Chief Financial Officer |
STOCK | 37.99K | $0 | Direct |
| Nov 14, 25 | BASSO STEPHEN Chief Financial Officer |
STOCK | 604 | $0 | Direct |
| Nov 3, 25 | RAIFELD PAVEL Beneficial Owner of more than 10% of a Class of Security |
STOCK | 112.30K | $2.00M | Direct |
| Nov 3, 25 | BASSO STEPHEN Chief Financial Officer |
STOCK | 27.61K | $500.00K | Direct |
| May 19, 25 | HAIMOVITZ JULES Director |
STOCK | 12.08K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BASSO STEPHEN |
Chief Financial Officer | 88.57K | Stock Award(Grant) |
DENNER ALEXANDER J |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
DIPAOLO MARK A |
Director | 140.49K | Stock Award(Grant) |
HAIMOVITZ JULES |
Director | 152.69K | Stock Award(Grant) |
LINDEN JOSEPHINE |
Director | 15.19K | Stock Award(Grant) |
RAIFELD PAVEL |
Chief Executive Officer | 285.93K | Stock Award(Grant) |
SCHLESINGER SARAH J |
Director | 140.49K | Stock Award(Grant) |
SMALL DEREK A |
Director | 45.03K | Stock Award(Grant) |
ZHEN MARIANNE Y |
Officer | 58.64K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
20.99
+0.36% from price
SMA 20
21.03
+0.18% from price
SMA 50
21.81
-3.39% from price
SMA 100
22.35
-5.73% from price
SMA 200
21.77
-3.21% from price
EMA 12
21.07
+0.02% from price
EMA 26
21.24
-0.79% from price
EMA 50
21.57
-2.33% from price
RSI (14)
47.4
Neutral
MACD (12,26,9)
-0.17
Hist 0.09
ATR (14)
0.57
2.70% of price
Realised vol 30D
23.8%
Annualised
Bollinger upper
21.72
20, 2σ
Bollinger lower
20.35
20, 2σ
50 / 200 cross
Golden
21.81 vs 21.77
Trend bias
Below 200
-3.21%
Risk profile
Beta vs SPY
-0.04
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
23.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-20.3%
Peak to trough
Max drawdown 5Y
-47.0%
Peak to trough
ATR 14
0.57
2.70% of price
Beta (reported)
0.34
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.14
Call-heavy session
Put / call open interest
0.17
Positioning, not flow
Max pain
20.00
-5.1% from spot
ATM implied vol
42.9%
Nearest strike to spot
Skew (10% OTM)
-17.7%
Calls bid over puts
Call volume
65
Contracts, this expiry
Put volume
9
Contracts, this expiry
Heaviest call OI
22.50
139 contracts
Heaviest put OI
22.50
34 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Business Wire · 11d ago
How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors
Simply Wall St. · 15d ago
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Zacks · 17d ago
Innoviva: Q2 Earnings Snapshot
Associated Press · 17d ago
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Business Wire · 17d ago
Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?
Insider Monkey · 52d ago
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform
Insider Monkey · 58d ago
Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally
Insider Monkey · 60d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.